Altimmune (NASDAQ:ALT) Stock Price Down 9.9%

Altimmune, Inc. (NASDAQ:ALTGet Rating) traded down 9.9% during trading on Friday . The stock traded as low as $11.92 and last traded at $12.03. 28,186 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 4,554,079 shares. The stock had previously closed at $13.35.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. HC Wainwright raised their target price on Altimmune from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, August 17th. JMP Securities reiterated a “buy” rating and set a $22.00 price target on shares of Altimmune in a research report on Wednesday, June 1st. Guggenheim dropped their price target on Altimmune from $31.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, September 16th. B. Riley lifted their price target on Altimmune from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, August 12th. Finally, Jefferies Financial Group lifted their price target on Altimmune from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 31st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Altimmune presently has an average rating of “Buy” and a consensus price target of $30.67.

Altimmune Trading Down 8.9 %

The company has a market capitalization of $596.20 million, a PE ratio of -5.37 and a beta of 0.19. The stock has a fifty day moving average of $15.70 and a two-hundred day moving average of $9.95.

Altimmune (NASDAQ:ALTGet Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.74 million. Altimmune had a negative return on equity of 47.54% and a negative net margin of 2,788.75%. During the same period last year, the firm posted ($0.40) EPS. Equities analysts forecast that Altimmune, Inc. will post -1.86 EPS for the current year.

Insider Activity at Altimmune

In other Altimmune news, CEO Vipin K. Garg sold 15,000 shares of Altimmune stock in a transaction that occurred on Friday, August 12th. The stock was sold at an average price of $15.06, for a total value of $225,900.00. Following the transaction, the chief executive officer now directly owns 259,804 shares of the company’s stock, valued at approximately $3,912,648.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Altimmune news, CEO Vipin K. Garg sold 15,000 shares of Altimmune stock in a transaction that occurred on Friday, August 12th. The stock was sold at an average price of $15.06, for a total value of $225,900.00. Following the transaction, the chief executive officer now directly owns 259,804 shares of the company’s stock, valued at approximately $3,912,648.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider M Scot Roberts sold 37,352 shares of Altimmune stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $12.00, for a total value of $448,224.00. Following the completion of the transaction, the insider now directly owns 17,700 shares in the company, valued at $212,400. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,588 shares of company stock valued at $1,392,554. Corporate insiders own 3.19% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently made changes to their positions in the business. Nuveen Asset Management LLC increased its stake in shares of Altimmune by 184.9% during the fourth quarter. Nuveen Asset Management LLC now owns 2,295,832 shares of the company’s stock valued at $19,400,000 after buying an additional 1,490,012 shares during the period. Vanguard Group Inc. increased its stake in shares of Altimmune by 4.8% during the first quarter. Vanguard Group Inc. now owns 1,816,915 shares of the company’s stock valued at $11,065,000 after buying an additional 83,160 shares during the period. D. E. Shaw & Co. Inc. increased its stake in shares of Altimmune by 23.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,181,237 shares of the company’s stock valued at $10,820,000 after buying an additional 225,799 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of Altimmune during the second quarter valued at approximately $10,999,000. Finally, Woodline Partners LP increased its stake in shares of Altimmune by 36.4% during the first quarter. Woodline Partners LP now owns 846,618 shares of the company’s stock valued at $5,156,000 after buying an additional 225,940 shares during the period. 81.03% of the stock is owned by hedge funds and other institutional investors.

About Altimmune

(Get Rating)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.

Featured Articles

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.